KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy for the treatment of advanced melanoma and metastatic non-small
cell lung cancer in patients whose disease has progressed after other
therapies, received the Prix Galien USA 2015 Award for Best
Biotechnology Product.
Language:
English
Contact: ...
Source: Merck.com - Corporate News - October 28, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Third-Quarter 2015 Financial Results
Dateline City:
KENILWORTH, N.J.
Increased Non-GAAP EPS by 7 Percent to $0.96; GAAP EPS of $0.64
Raised 2015 Full-Year Non-GAAP EPS Target to a Range of $3.55 – $3.60 and GAAP EPS Target to a Range of $1.64 – $1.74
Worldwide Sales Were $10.1 Billion, a Decrease of 5 Percent; Excluding the Impact of Foreign Exchange, Acquisitions and Divestitures, Worldwide Sales Grew 4 Percent
Advanced KEYTRUDA Program
FDA Approved sBLA for the ...
Source: Merck.com - Corporate News - October 27, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Dateline City:
KENILWORTH, N.J.
KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the National Institute for Health and Care Excellence
(NICE) of the United Kingdom (U.K.) has issued a draft recommendation,
in the form of a Final Appraisal Determination (FAD), recommending
KEYTRUDA® (p...
Source: Merck.com - Corporate News - October 9, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
Dateline City:
KENILWORTH, N.J.
Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
proudly congratulates William C. Campbell, a retired scientist from
Merck Research Laboratories, who was jointly named the 2015 Nobel Prize
winner in Physiology or Medicine with Satoshi Omura for the discovery of
avermectin, ...
Source: Merck.com - Corporate News - October 5, 2015 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
International Coalition Urges Final Push to Eliminate River Blindness from the Americas
Dateline City:
WASHINGTON, ATLANTA, & KENILWORTH, N.J.
Country efforts supported by a major public-private partnership - including The Carter Center/OEPA, PAHO/WHO, and Merck & Co., Inc.’s Mectizan Donation Program - bring the region closer to achieving the elimination goal by 2020
Mexico latest country to receive verification of elimination by World Health Organization
WASHINGTON, ATLANTA, & KENILWORTH, N.J.--(BUSINESS WIRE)--The Carter Center, PAHO/WHO an...
Source: Merck.com - Corporate News - September 29, 2015 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
Dateline City:
KENILWORTH, N.J.
KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients
Results from KEYNOTE-028 Presented at 2015 European Cancer Congress
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings investigating
the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy, as a monotherap...
Source: Merck.com - Corporate News - September 26, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its third-quarter 2015 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct.
27. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - September 25, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, chairman and chief executive
officer, and Dr. Roger M. Perlmutter, president of Merck Research
Laboratories, are scheduled to participate at the Morgan Stanley Global
Healthcare Conference in New York on Sept. 17, 2015 at 8:35 a.m. EDT.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - September 16, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Publishes 2014 Global Corporate Responsibility Report
Dateline City:
KENILWORTH, N.J.
Online Report Demonstrates Commitment to Operating as a Responsible Business and Highlights Progress in Addressing Global Health and Development Challenges
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today issued its 2014
global corporate responsibility report, which provides an overview
of its priorities, programs and performance in the areas of Access to
Health, En...
Source: Merck.com - Corporate News - September 10, 2015 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved a supplemental New Drug Application (sNDA) for EMEND®
(aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor
antagonist.
Language:
English
Contact:
MerckMedia:Doris Li, 908-740-1903An P...
Source: Merck.com - Corporate News - September 2, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Pamela J. Craig, retired chief financial officer of
Accenture, and Dr. Paul B. Rothman, dean of the medical faculty, vice
president for medicine of The Johns Hopkins University and chief
executive officer of Johns Hopkins Medicine, will join the company’s
board of directors, effective Sept. 1, 2015.
Language:
English
...
Source: Merck.com - Corporate News - July 28, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Second-Quarter 2015 Financial Results
Dateline City:
KENILWORTH, N.J.
Second-Quarter 2015 Non-GAAP EPS of $0.86, Excluding Certain Items; GAAP EPS of $0.24
Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.52 to $1.71
Second-Quarter 2015 Worldwide Sales Were $9.8 Billion, a Decrease of 11 Percent, Including a 7 Percent Net Unfavorable Impact from Acquisitions and Divestitures and a ...
Source: Merck.com - Corporate News - July 28, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
Dateline City:
KENILWORTH, N.J. & MISGAV, Israel
KENILWORTH, N.J. & MISGAV, Israel--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
cCAM Biotherapeutics announced today that the companies have signed a
definitive agreement under which Merck will acquire cCAM
Biotherapeutics, a privately held biopharmaceutical company focused on
the discovery and development of novel cancer immunotherapies.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - July 28, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA™ (Ceftolozane and Tazobactam)
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of the investigational antibiotic ZERBAXA™
(ceftolozane and tazobactam) for the treatment of the following
infections in adults: complicated intra-abdominal infections, acute
pyelonephritis, and complicated urinary tract i...
Source: Merck.com - Corporate News - July 27, 2015 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Fourth-Quarter 2015 Dividend
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.45 per share of the company’s common stock for the fourth
quarter of 2015. Payment will be made on October 7, 2015, to
shareholders of record at the close of business on September 15, 2015.
About Merck
Language:
English
Contact:
...
Source: Merck.com - Corporate News - July 22, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
